A new umbrella review reveals how GLP-1 therapies shape cardiovascular, renal, and metabolic outcomes in type 2 diabetes while highlighting drug-specific advantages and the need to manage gastrointestinal risks
Sustained inhibition of NPY/AgRP neuronal activity by FGF1
According to the Food and Drug Administration (FDA), When a manufacturer applies for FDA approval of a drug, regulations require them to provide stability testing with a recommended expiration date and storage conditions
If you are coming from another GLP-1 agonist, reading the semaglutide to tirzepatide conversion chart or the switching dosage chart can help you decide where in the retatrutide titration to begin
Schedule a free consultation
Researchers also conducted an analysis using data from the WHOs pharmacovigilance database from April 28, 2005, to March 1, 2021